Literature DB >> 26572509

Impact of delay between imaging and treatment in patients with potentially curable pancreatic cancer.

S Sanjeevi1, T Ivanics2, L Lundell3, N Kartalis4, Å Andrén-Sandberg3, J Blomberg3, M Del Chiaro3, C Ansorge3.   

Abstract

BACKGROUND: Locoregional pancreatic ductal adenocarcinoma (PDAC) may progress rapidly and/or disseminate despite having an early stage at diagnostic imaging. A prolonged interval from imaging to resection might represent a risk factor for encountering tumour progression at laparotomy. The aim of this study was to determine the therapeutic window for timely surgical intervention.
METHODS: This observational cohort study included patients with histologically confirmed PDAC scheduled for resection with curative intent from 2008 to 2014. The impact of imaging-to-resection/reassessment (IR) interval, vascular involvement and tumour size on local tumour progression or presence of metastases at reimaging or laparotomy was evaluated using univariable and multivariable regression. Risk estimates were approximated using hazard ratios (HRs).
RESULTS: Median IR interval was 42 days. Of 349 patients scheduled for resection, 82 had unresectable disease (resectability rate 76.5 per cent). The unresectability rate was zero when the IR interval was 22 days or shorter, and was lower for an IR interval of 32 days or less compared with longer waiting times (13 versus 26.2 per cent; HR 0.42, P = 0.021). It was also lower for tumours smaller than 30 mm than for larger tumours (13.9 versus 32.5 per cent; HR 0.34, P < 0.001). Tumours with no or minor vascular involvement showed decreased rates of unresectable disease (20.6 per cent versus 38 per cent when there was major or combined vascular involvement; HR 0.43, P = 0.007). However, this failed to reach statistical significance on multivariable analysis (P = 0.411), in contrast to IR interval (P = 0.028) and tumour size (P < 0.001).
CONCLUSION: Operation within 32 days of diagnostic imaging reduced the risk of tumour progression to unresectable disease by half compared with a longer waiting time. The results of this study highlight the importance of efficient clinical PDAC management.
© 2015 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 26572509     DOI: 10.1002/bjs.10046

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  21 in total

1.  Unnecessary preoperative biliary drainage: impact on perioperative outcomes of resectable periampullary tumors.

Authors:  Jean-Baptiste Cazauran; Julie Perinel; Vahan Kepenekian; Michel El Bechwaty; Gennaro Nappo; Mathieu Pioche; Thierry Ponchon; Mustapha Adham
Journal:  Langenbecks Arch Surg       Date:  2017-10-31       Impact factor: 3.445

2.  Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox.

Authors:  Stephan Kruger; Karoline Schirle; Michael Haas; Alexander Crispin; Jörg Schirra; Julia Mayerle; Jan G D'Haese; Wolfgang G Kunz; Jens Ricke; Steffen Ormanns; Thomas Kirchner; Sebastian Kobold; Matthias Ilmer; Leonie Gebauer; Christoph B Westphalen; Michael von Bergwelt-Baildon; Jens Werner; Volker Heinemann; Stefan Boeck
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-23       Impact factor: 4.553

3.  The Additional Value of Laparoscopic Ultrasound to Staging Laparoscopy in Patients with Suspected Pancreatic Head Cancer.

Authors:  Gijs A Looijen; Bobby K Pranger; Koert P de Jong; Jan Pieter Pennings; Vincent E de Meijer; Joris I Erdmann
Journal:  J Gastrointest Surg       Date:  2018-03-12       Impact factor: 3.452

4.  'Fast-track' pathway for resectable pancreatic cancer: barriers and facilitators to implementation across a regional network.

Authors:  Basil Yannoulias; Mark Exworthy; Keith J Roberts
Journal:  Future Healthc J       Date:  2021-11

5.  Liver metastases in pancreatic ductal adenocarcinoma: a predictive model based on CT texture analysis.

Authors:  Riccardo De Robertis; Luca Geraci; Luisa Tomaiuolo; Luca Bortoli; Alessandro Beleù; Giuseppe Malleo; Mirko D'Onofrio
Journal:  Radiol Med       Date:  2022-09-04       Impact factor: 6.313

Review 6.  Surgical safety in the COVID-19 era: present and future considerations.

Authors:  Young Il Kim; In Ja Park
Journal:  Ann Surg Treat Res       Date:  2022-06-07       Impact factor: 1.766

7.  Waiting time for cancer treatment and mental health among patients with newly diagnosed esophageal or gastric cancer: a nationwide cohort study.

Authors:  Huan Song; Fang Fang; Unnur Valdimarsdóttir; Donghao Lu; Therese M-L Andersson; Christina Hultman; Weimin Ye; Lars Lundell; Jan Johansson; Magnus Nilsson; Mats Lindblad
Journal:  BMC Cancer       Date:  2017-01-03       Impact factor: 4.430

8.  Development and multicentre validation of a prognostic model to predict resectability of pancreatic head malignancy.

Authors:  K Gerken; K J Roberts; B Reichert; R P Sutcliffe; F Marcon; S K Kamarajah; A Kaltenborn; T Becker; N G Heits; D F Mirza; J Klempnauer; H Schrem
Journal:  BJS Open       Date:  2018-06-08

9.  Gastrointestinal Malignancies and the COVID-19 Pandemic: Evidence-Based Triage to Surgery.

Authors:  Scott C Fligor; Sophie Wang; Benjamin G Allar; Savas T Tsikis; Ana Sofia Ore; Ashlyn E Whitlock; Rodrigo Calvillo-Ortiz; Kevin R Arndt; Sidhu P Gangadharan; Mark P Callery
Journal:  J Gastrointest Surg       Date:  2020-06-30       Impact factor: 3.452

10.  Has the non-resection rate decreased during the last two decades among patients undergoing surgical exploration for pancreatic adenocarcinoma?

Authors:  C Mattevi; J Garnier; U Marchese; J Ewald; M Gilabert; F Poizat; G Piana; J R Delpero; O Turrini
Journal:  BMC Surg       Date:  2020-08-05       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.